We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Henry Schein Inc | NASDAQ:HSIC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -0.72% | 68.78 | 67.91 | 72.44 | 69.84 | 68.59 | 69.38 | 890,008 | 22:30:00 |
By Chris Wack
Henry Schein Inc. said Wednesday it will serve as the exclusive distributor in the U.S. of a second point-of-care rapid test kit that can detect antibodies associated with Covid-19 in as few as 15 minutes.
The health-care technology company said it is working with Becton Dickinson & Co. and BioMedomics, a privately held clinical diagnostics company, to make the test kits available to health-care professionals.
The BioMedomics test analyzes blood, serum or plasma samples for the presence of Immunoglobulin M and Immunoglobulin G antibodies associated with the coronavirus. The test is completed in four steps. The results can be read in 15 minutes.
The company said it is also a participant in the White House's Covid-19 Supply Chain Task Force, and has worked with the Strategic National Stockpile to deliver personal protective equipment to Covid-19 testing sites, and is working with the Federal Emergency Management Agency to source and deliver critical supplies quickly.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 01, 2020 07:30 ET (11:30 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Henry Schein Chart |
1 Month Henry Schein Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions